Brookfield Medical/Surgical Supply, Inc., Brookfield, CT
Is Brookfield Medical/Surgical Supply, Inc. an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Brookfield Medical/Surgical Supply, Inc. in Brookfield, CT, first registered Jan 12, 2015 and most recently registered Dec 30, 2025. FDA lists its last inspection as Jul 10, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Brookfield, CT
- Initial registration
- Jan 12, 2015
- Most recent registration
- Dec 30, 2025
- Last inspection
- Jul 10, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Open
- Intends to compound sterile drugs from bulk substances
- Yes
- Earlier inspections
- FDA notes that an earlier inspection led to a Form 483, warning letter or other action
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Brookfield Medical/Surgical Supply, Inc., Brookfield, CT, a 503B facility, with 6 listed actions, including 3 Form 483s and 1 untitled letter (2022 to 2026).
| Document | |||
|---|---|---|---|
| Jul 10, 2026 | Form 483 | 483 Issued 07/10/2026 | fda.gov |
| Feb 13, 2025 | FMD-145 letter | FMD-145 Letter Issued 02/13/2025 | Not linked by FDA |
| Sep 27, 2024 | Untitled letter | Untitled Letter Issued 09/27/2024 | fda.gov |
| May 10, 2024 | Form 483 | 483 Issued 05/10/2024 | FDA copy (archived) |
| Feb 6, 2023 | FMD-145 letter | FMD-145 Letter Issued 02/06/2023 | Not linked by FDA |
| Apr 4, 2022 | Form 483 | 483 Issued 04/04/2022 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Brookfield Medical/Surgical Supply, Inc., Brookfield, CT (FEI number 3011430551), matched to this page by exact name, city and state. It lists 4 inspections: 2 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| May 10, 2024 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011430551 | 1238439 |
| Dec 21, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011430551 | 1075504 |
| Apr 18, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011430551 | 1009608 |
| Apr 9, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011430551 | 924250 |
Form 483s FDA has published for this site
- Jul 10, 2026: Form 483 to Brookfield Medical/Surgical Supply, Inc., published Sep 10, 2026. fda.gov
- May 10, 2024: Form 483 to Brookfield Medical/Surgical Supply, Inc., published Jun 28, 2024. fda.gov
- Apr 4, 2022: Form 483 to Brookfield Medical/Surgical Supply, Inc., published Sep 22, 2022. fda.gov
- Dec 21, 2018: Form 483 to Brookfield Medical/Surgical Supply, Inc., published Apr 30, 2019. fda.gov
- Sep 27, 2017: Form 483 to Brookfield Medical/Surgical Supply, Inc., published Jan 17, 2024. fda.gov
- Aug 3, 2017: Form 483 to Brookfield Medical/Surgical Supply, Inc., published Jan 17, 2024. fda.gov
- May 24, 2017: Form 483 to Brookfield Medical/Surgical Supply, Inc., published Jan 17, 2024. fda.gov
- Jul 17, 2015: Form 483 to Brookfield Medical/Surgical Supply, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 16 numbered observations in all, across 3 inspections ending Dec 21, 2018 to Jul 10, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jun 29, 2026 to Jul 10, 2026: 3 observations
- Firm on the cover
- Brookfield Medical/Surgical Supplies, I nc., 60 Old New Milford Rd Ste 1b, Brookfield, CT 0680 4-2429
- FEI number
- 3011430551
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 109 Holton Street Winchester, MA 01890
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
Your firm failed to adequately investigate Out-of-Specification (OOS) results for potency testing of sterile drug products manufactured during May 2024-June 2026. A review of deviation records revealed thirteen (13) OOS potency failures across multiple drug products and lots, indicates a recurring and systemic failure to maintain adequate process controls.
All 00S were reportedly attributed to the contract testing laboratory and resolved via retesting at the same lab.
Table below shows all the potency OOS:
Deviation #
Date Initiated
Vials
Type
Drug Product
Lot Number(s)
Close Date
October 4, 2024
Redacted B4
September 19,2024
OOS Potency
Triamcinolone Acetonide
DV24·051
091124·1
April 9,
DV25-053 April 3, 2025 OOS Potency
Morphine Sulfate
DV25-054 April 7, 2025
OOS Methylprednisolon 033125-1 April 14, 2025
I l Potency e Acetate 2025 i DV25-0SS June 9, 2025 i OOS Potency
Sodium Phosphate 060425-1 I June 26, 2025 (b) (4)
~ I
IBetamethasone
DV25·056 July 3, 2025 ...
Observation 2
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically,
Your quality control unit failed to exercise adequate oversight of the contract testing laboratory performing potency testing (refer to the table in Observation 1) as evidenced by:
(1) Pattern of OOS invalidation without adequate QCU scrutiny Thirteen (13) Out-of-Specification (OOS) potency results were recorded over 26 months between May 2024 and June 2026 across four drug products (Triamcinolone Acetonide, Betamethasone Sodium Phosphate, Methylprednisolone Acetate, and Morphine Sulfate). Twelve (1 2) of these OOS results were invalidated and product was released without documented evidence that the quality control unit independently reviewed the contract laboratory's raw data, chromatograms, instrument logs and invalidation rationale. One result (Triamcinolone Acetonide 3mL, Lot 051526-1) was confirmed 00S, The QCU accepted the contract lab's invalidation conclusions in 12 of 13 cases without apparent independent verification. For DV25-058 (Betamethasone lot 091 225-1), the contract testing laboratory stated the root cause was undetermined. ...
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Specifically,
The environmental monitoring program ofyour firm allows for a CFU limit <Redacted B4> for gloved fingertips in an ISO 5 area. For a COMP compliant 503B facility, the action level must be any detected organism. Furthermore, your firm failed to investigate and identity the microbial growth recovered from the ISO 5 environment at the facility. All the compounded drug products were released for distribution.
The environmental monitoring (EM) excursion records below document nine (9) microbial excursions occurring in ISO-5 classified areas between May 8, 2025, and June 24, 2026. Of these, five (5) involved gloved fingertip samples, three (3) involved personne] <Redacted B4> samples, and one (1) involved a surface sample.
All samples yielded 1 CFU on <Redacted B4>, exceeding the action level of <Redacted B4> 1CFU established for ISO-5 areas. Only one excursion (No. 39, dated 2026-05-21) which involved a surface sample from location ISO <Redacted B4> was identified as a Bacillus Species. ...
Inspection Mar 21, 2022 to Apr 4, 2022: 5 observations
- Firm on the cover
- Brookfield Medical/Surgical Supply, Inc., 60 Old New Milford Rd Ste lB, Brookfield, CT 06804-2429
- FEI number
- 3011430551
- Establishment type on the cover
- 503B Outsourcing Facility
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Buildings used in the manufacturing, processing and holding of a drug product are not maintained in a good state of repair.
Specifically,
• Brownish rust-like material was observed on the <Redacted B4> bracket for the hanging bar within the interior of the firm's ISO-5 lamina flow hood. The hood is utilized for the aseptic production of the firm's solutions: Betamethasone Sodium Phosphate and <Redacted B4.>. In addition the hood is utilized in the production of the following terminally sterilized suspensions: Methylprednisolone Acetate and Triamcinolone.
• Chipped paint was observed on the door damper on the interior side of the IS0-8 Ante Room door. The Ante Room is utilized for the following activities: sterile gowning, weighing operations and formulation activities.
• Brownish stains were observed on the bottom and sides within the Prep Room sink. The sink is located in the unclassified Prep Room and is utilized in the <Redacted B4> washing of the <Redacted B4> used for the firm's production activities.
Observation 2
Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the dmg product.
Specifically,
- The firm routinely uses a household cleaner <Redacted B4> for the washing of all glassware and equipment utilized in the production of the firm's finished drug products. The firm has no evidence that the household cleaner used is capable of removing pharmaceutical residues or if there are any residues left behind on the glassware by the household cleaner.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically,
The firm's smoke studies that were conducted by <Redacted B4> in 2021 were inadequate. The dynamic studies that were conducted for the non-terminally sterilized products (solutions) fail to include a full assessment of all ISO-7 and ISO-5 air interactions to demonstrate <Redacted B4> airflow and sweeping action over and away from sterile product under dynamic conditions.
Observation 4
The calibration of instruments is not done at suitable intervals in accordance with an established written program.
Specifically,
Observation 5
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality and purity they purport or are represented to possess.
Specifically,
The firm failed to define release criteria in their SOP "Visual Inspection of Sterile Drug Products", or batch records by failing to define what constitutes as a minor, major, or critical defect. Which doesn't ensure consistency of defects noted between the different qualified visual inspectors.
For example,
The firm's visual inspection is documented in the batch record which includes the following objectionable defects: Defect, Large Particle Sizes, Suspension Stuck to Vial, Volume, Suspension Height, Inert Ingredients, Color, and Growth for Suspension products and Defect, Volume, Color, Particulate, Not in Solution, Coring, Inconclusive, and Growth for Solution products. There is no definition in the batch record or SOP which establishes what constitutes as a minor, major, or critical defect. In addition, the firm's Visual Inspection test kits do not include all of the known defects such as Growth.
Inspection Dec 10, 2018 to Dec 21, 2018: 8 observations
- Firm on the cover
- Brookfield Medical/Surgical Supply, I nc., 60 Old New Milford Rd St e l B
- FEI number
- 3011430551
- Establishment type on the cover
- 503B Ou tsourcing Facili ty Brookfield, CT 06804 - 2429
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
There are no written procedures for production and process controls designed to assure that the chug products have the identity, strength, quality, and purity they purport or are represented to possess. Specifically, The fnm failed to validate the manufacturing processes for sterile chug products. For example:
• At the time of the inspection (12/10/2018), the firm had not completed the Process Validation for
the 3mL and 5mL Triamcinolone Acetonide Suspension 40mg/mL for Injection drug products.
• At the time of the inspection (12/10/2018), the firm had not staited the Process Validation for the 5mL Methylprednisolone Acetate Suspension 40mg/mL for injection.
Furthermore, the firm has manufacture d-lots REDACTED (b)(4) of Methylprednisolone Acetate S uspension 40mg/m L for injection, REDACTED (b)(4) lots of Triamcinolone Aceton id e Suspen sion 40mg/mL (3mL), and REDACTED (b)(4) lots of Triamcinolone Acetonide Suspension 40mg/mL (5mL) without validating the manufacturing processes since their Regulatory Meeting with the FDA on January 8, 2018.
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
a. The firm does not have scientific justification for not monitoring environmental conditions throughout manufacturing operations within the ISO 5 Laminar Flow Hood (LFH). The pharmacy technicians will remove the non-viable particulate monitor from the ISO 5 LFH after REDACTED (b)(4) of run time. The haimac technicians will remove the viable air sampler after measuring with REDACTED (b)(4) each. The remaining manufacturing operations which can be REDACTED (b)(4) depending on the fill size are conducted without monitoring environmental conditions. The manufacturing activities within this hood include REDACTED (b)(4) sterilized products, Methylprednisolone Acetate (40mg/mL), Triamcinolone Acetonide (40mg/mL) and one aseptically filled product, Betamethasone Sodium (6mg/mL).
b. The firm does not monitor the differential pressure of the ISO 5 Laminair Flow Hood during manufacturing operations. The firm uses this ISO 5 LFH to manufacture REDACTED (b)(4) sterilized products and REDACTED (b)(4) filled product on a routine basis. ...
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions. Specifically,
The firm failed to conduct a disinfectant efficacy study to determine the effectiveness of the cleaning agents utilized by the firm on the surfaces of the facility and equipment used in the manufacturing process of the firm's sterile drug products.
Observation 4
Each lot of a component that is liable to microbiological contamination that is objectionable in view of its intended use is not subjected to microbiological tests before use.
Specifically,
The firm' s process for evaluating incoming Active Pharmaceutical Ingredients (Bulk Drug Substances) used to manufacture sterile drug products Methylprednisolone Acetate ( 40mg/mL ), Triamcinolone Acetonide ( 40mg/mL) and Betamethasone Sodium ( 6mg/mL) is inadequate in that the firm has not established specifications for or routinely test for bioburden and endotoxins as part of their release specification. For example, the following was noted:
• On 08/22/2018, Betamethasone Sodium Phosphate lot number REDACTED (b)(4) was used to manufacture REDACTED (b)(4) vial of Betamethasone Sodium ( 6mg/mL) batch number 082318-1 which were released by Quality on 09/24/2018 without having endotoxin testing completed prior to use in production. ...
Observation 5
Procedures designed to prevent microbiological contamination of drug products purport ing to be sterile are not followed.
Specifically,
On December 13, 2018, we observed the following:
• Operators REDACTED (b)(4) and REDACTED (b)(4) were observed moving sterile vials and equipment within the IS0-5 hood during the manufacturing of Triamcinolone Acetonide lot# 121318-1 and several instances were noted in which the top of the head and parts of the shoulders of these operators entered the hood.
• Operator REDACTED (b)(4) was observed conducting end of day cleaning operations within the firm's classified areas (IS0-8, IS0-7, and IS0-5). The operator was noted to be wearing sterile gloves, a steri le hood, sterile goggles and a sterile smock. The operator's lower legs were exposed with non-sterile s crubs, socks and footwear during the cleaning operations.
Observation 6
Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically,
• The firm utilizes balance REDACTED (b)(4) in the weighing of all REDACTED (b)( 4) raw materials used to manufacture the firm's finished drug products. The firm conducts calibration of the balance prior to use with the foll owing certified weights: REDACTED (b)(4 ) Review of the firm's batch records for Methylpre dnisolone Acetate revealed that the firm routine ly weighs the Methylprednisolone A cetate a ctive ingredient in increments of REDACTED (b)(4) and the REDACTED (b)(4) raw material in increments of REDACTED (b)(4).
• The firm utilizes pH meters to check the pH of the formulation prior to filling of the firm's finished drug products. The firm conducts ca libration of the pH meter with the following pH buffer solutions: REDACTED (b)(4) Review of the firm's batch records for Betamethasone Sodium Phosphate revealed that the pH specifications for the Betamethasone drug product are between REDACTED (b)(4)
Observation 7
The firm has failed to collect retain samples for any of the finished drug products (Triamcinolone Acetonide, Methylprednisolone Acetate and Betamethasone Sodium Phosphate) that have been manufactured since the firm began operations in 2015.
Observation 8
You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503B(d)(2). Specifically, You compound drug products that: a) are identical or nearly identical to an approved drug that is not on the drug shortage list in effect under section 506E at the time of compounding, distribution, and dispensing; or b) are not identical or nearly identical to an approved drug, but contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.
Linked 483s whose text is not shown
- May 10, 2024: FDA document 179540: the FEI number and firm name on its cover do not match this page by the rule.
- Aug 3, 2017: FDA document 106664: its numbered observations could not be read reliably from the PDF text.
- May 24, 2017: FDA document 104902: the FEI number and firm name on its cover do not match this page by the rule.
- Jul 17, 2015: FDA document 91905: its numbered observations could not be read reliably from the PDF text.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Brookfield Medical/Surgical Supply, Inc.). That is not a finding beyond this index’s search.
The Brookfield Medical/Surgical Supply, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.